V
Visterra
Biotech & Life Sciences · Cambridge, United States · Founded 2007
Developing transformative biologics for immune-mediated and hard-to-treat diseases MoreLess
Visterra is a biologics research and early-stage clinical development company focused on creating therapies for patients suffering from immune-mediated and other challenging diseases. The company operates in the biotechnology sector, primarily serving patients with conditions in nephrology, rheumatology, transplant immunology, and neurology. Visterra's business model revolves around the research, development, and early clinical testing of biologic drugs, leveraging cutting-edge technologies to engineer novel therapies. The company generates revenue through partnerships, licensing agreements, and the eventual commercialization of its developed therapies. As part of the Otsuka family of companies, Visterra benefits from the support and stability of a long-established global entity while maintaining the agility and innovation of a smaller organization. The company also offers a Co-Op program to provide students with valuable industry experience and exposure to innovative research and technologies.
Keywords: biologics, immune-mediated diseases, nephrology, rheumatology, transplant immunology, neurology, early-stage clinical development, biotechnology, innovative therapies, Otsuka family.
Company overview
Visterra company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2007
- Headquarters
- Cambridge, United States
- Employees
- 133
- Open positions
- 4
- Dealroom signal
- 76.1
Valuation & funding
Visterra funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2018 | $430M | — | Otsuka Pharmaceutical | — |
| SERIES COther financing | Oct 2017 | $47M | $187M | Polaris Partners · Vertex Holdings · Cycad Group · Omega Funds | ↗ |
| SERIES COther financing | Jun 2016 | $23M | $92M | Undisclosed | — |
| SERIES BOther financing | Oct 2014 | $30M | $120M | Temasek | — |
| SERIES AOther financing | Dec 2013 | $8.1M | $32M | Undisclosed | — |
| SERIES AOther financing | Nov 2012 | Undisclosed | — | ||
| DEBTDebt | Aug 2010 | Lux Capital · Polaris Partners · Flagship Pioneering | — | ||
| EARLY VCOther financing | Dec 2009 | Undisclosed | — | ||
| SEEDOther financing | May 2009 | Undisclosed | — | ||
| SEEDOther financing | Feb 2008 | Undisclosed | — |
Growth signals
Visterra website traffic
Latest recorded traffic for Visterra is 5K monthly website visits, down 9.1% over the last three months. Visterra's team grew 47.8% over the past year.
Hiring
Open positions at Visterra
Current openings linked to this company in Dealroom.
Comparisons
Visterra compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Visterra's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Visterra has talent and traffic
team presence
In the news
Latest news about Visterra
Recent press, funding announcements, and product moves mentioning Visterra — open to read from the original sources.
Market sentiment
What the market is saying about Visterra
An AI-synthesized read of the highest-engagement posts about Visterra on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Visterra’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.